Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 80

Sort by

Sort Order Select

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao, Jeremy Eisele, Leah Gehrs, Julie K. Ritchey, Jaebok Choi, Camille N Abboud, Iskra Pusic, Meagan A Jacoby, Peter Westervelt, Matthew Christopher, Amanda F. Cashen, Armin Ghobadi, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio

Blood blood.2024026497.

https://doi.org/10.1182/blood.2024026497

Published: 2024

Includes: Supplemental data

Journal Articles

Asciminib (ASC) Once-Daily (QD) Dosing Demonstrates Comparable Tolerability and Efficacy to Twice-Daily (BID) Dosing: Results from the ASC in Monotherapy 4 CML (AIM4CML) Study in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

David Andorsky, Ghayas C. Issa, Edward R Broun, Camille N. Abboud, Michael W. Deininger, Michael Mauro, Andrea Damon, Natasha Porter, Najma Ashraf, Moshe Levy

Blood (2023) 142 (Supplement 1): 3172.

https://doi.org/10.1182/blood-2023-187357

Published: 2023

Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Blood (2023) 142 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2023-187433

Published: 2023

Journal Articles

Targeting CDK8/CDK19 to Disrupt Leukemic Stem Cell-like Population in Acute Myeloid Leukemia: Exploring RVU120 As a Promising Frontline Therapy

Milena Mazan, Urszula Pakulska, Adrianna Moszyńska, Agnieszka Sroka-Porada, Krzysztof Tomasz Szade, Michał Mikula, Magdalena Kozakowska, Przemysław Juszczyński, Katarzyna Wiklik, Kristina Göller, Marta Obacz, Camille N. Abboud, Jan Maciej Zaucha, Ewa Lech Marańda, Noemi Angelosanto, Hendrik Nogai, Tomasz Rzymski

Blood (2023) 142 (Supplement 1): 4175.

https://doi.org/10.1182/blood-2023-188866

Published: 2023

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P. Rettig, Feng Gao, Julie K. Ritchey, Camille N. Abboud, Iskra Pusic, Peter Westervelt, Amanda F Cashen, Matt Christopher, Armin Ghobadi, Ramzi Abboud, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio, Leah Gehrs

Blood (2023) 142 (Supplement 1): 651.

https://doi.org/10.1182/blood-2023-180289

Published: 2023

Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Blood (2023) 142 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2023-189040

Published: 2023

Journal Articles

Preclinical and Clinical Evidence for Erythroid-Stimulating Activity of RVU120 CDK8/19 Inhibitor in AML and MDS

Noemi Angelosanto, Ewa Lech Marańda, Jan Maciej Zaucha, Camille N. Abboud, Agnieszka Sroka-Porada, Wiktoria Ogrodzińska, Magdalena Kozakowska, Urszula Głowniak-Kwitek, Karolina Bukowska-Strakova, Tomasz Rzymski, Milena Mazan, Urszula Pakulska, Kristina Göller, Ewa Zarzycka, Hendrik Nogai

Blood (2023) 142 (Supplement 1): 2800.

https://doi.org/10.1182/blood-2023-189064

Published: 2023

Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Blood (2023) 142 (Supplement 1): 469.

https://doi.org/10.1182/blood-2023-182177

Published: 2023

Journal Articles

Safety and Efficacy Results from CLI120-001 a Phase 1 Study in RR-AML and HR-MDS: Update from Higher Dose Levels

Blood (2023) 142 (Supplement 1): 2913.

https://doi.org/10.1182/blood-2023-186620

Published: 2023

Journal Articles

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Blood (2022) 139 (8): 1177–1183.

https://doi.org/10.1182/blood.2021011532

Published: 2022

Includes: Supplemental data

Journal Articles

Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Eunice S. Wang, MD, Richard Aplenc, MD PhD, Deborah Chirnomas, Michael John Dugan, MD, Salman Fazal, MD, Swaminathan Iyer, Tara L Lin, MD, Sucha Nand, MD, Kristen J Pierce, Paul J Shami, MD, Jennifer J Vermette, Camille N Abboud, MD

Blood (2018) 132 (Supplement 1): 3979.

https://doi.org/10.1182/blood-2018-99-110804

Published: 2018

Journal Articles

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy

Blood (2018) 132 (Supplement 1): 1407.

https://doi.org/10.1182/blood-2018-99-117231

Published: 2018

Journal Articles

Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial)

Blood (2018) 132 (Supplement 1): 3027.

https://doi.org/10.1182/blood-2018-99-111935

Published: 2018

Journal Articles

Clinical Characteristics of Isolated CNS Relapse after Allogeneic Transplantation for AML — Poor Outcomes Despite Longer Time to Relapse

Pavan Kumar Bhamidipati, MBBS, MD, Armin Ghobadi, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Feng Gao, PhD, Peter Westervelt, MDPhD, Geoffrey L. Uy, MD, Camille N. Abboud, MD, Mark A. Schroeder, MD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 4566.

https://doi.org/10.1182/blood.V130.Suppl_1.4566.4566

Published: 2017

Journal Articles

FLT3 Positivity Is a Predictor of Early Relapse Post-Transplantation — Allo-HCT Is an Ineffective Salvage Strategy in Active AML

Pavan Kumar Bhamidipati, MBBS, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Feng Gao, PhD, Mark A. Schroeder, MD, Ravi Vij, MDMBA, Amanda F. Cashen, MD, Camille N. Abboud, MD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 4567.

https://doi.org/10.1182/blood.V130.Suppl_1.4567.4567

Published: 2017

Journal Articles

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

Geoffrey L. Uy, MD, Michael P Rettig, PhD, Theresa Fletcher, Peter A Riedell, MD, Keith E. Stockerl-Goldstein, MD, Armin Ghobadi, MD, Meagan Jacoby, MD PhD, Amanda F. Cashen, MD, Rizwan Romee, MD, Iskra Pusic, MD, Camille N. Abboud, MD, Mark A. Schroeder, MD, Ravi Vij, MDMBA, Peter Westervelt, MDPhD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 816.

https://doi.org/10.1182/blood.V130.Suppl_1.816.816

Published: 2017

Journal Articles

Pretransplant Clinical Factors Can be Used to Predict the Risk of Cytokine Release Syndrome after Haploidentical Peripheral Blood Transplantation

Ramzi Abboud, MD BS, Kathryn Trinkaus, PhD, John F DiPersio, MD PhD, Camille N. Abboud, MD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 1967.

https://doi.org/10.1182/blood.V130.Suppl_1.1967.1967

Published: 2017

Journal Articles

Outcomes of Patients with Baseline Marrow Fibrosis at Allogeneic Hematopoietic Cell Transplantation

Pavan Kumar Bhamidipati, MBBS, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Ningying Wu, PhD, Ravi Vij, MDMBA, Amanda F. Cashen, MD, John F DiPersio, MD PhD, Camille N. Abboud, MD

Blood (2017) 130 (Supplement 1): 3204.

https://doi.org/10.1182/blood.V130.Suppl_1.3204.3204

Published: 2017

Journal Articles

Tocilizumab Is Safe after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Ramzi Abboud, MD BS, Michael Slade, MDMS, Kathryn Trinkaus, PhD, Camille N. Abboud, MD, John F DiPersio, MD PhD, Todd A. Fehniger, MDPhD, Geoffrey L. Uy, MD, Peter Westervelt, MDPhD, Ravi Vij, MDMBA, Mark A. Schroeder, MD, Iskra Pusic, MD, Armin Ghobadi, MD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 3213.

https://doi.org/10.1182/blood.V130.Suppl_1.3213.3213

Published: 2017

Journal Articles

Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft

Blood (2017) 129 (19): 2680–2692.

https://doi.org/10.1182/blood-2016-09-739722

Published: 2017

Includes: Supplemental data

NARROW

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

Asciminib (ASC) Once-Daily (QD) Dosing Demonstrates Comparable Tolerability and Efficacy to Twice-Daily (BID) Dosing: Results from the ASC in Monotherapy 4 CML (AIM4CML) Study in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Targeting CDK8/CDK19 to Disrupt Leukemic Stem Cell-like Population in Acute Myeloid Leukemia: Exploring RVU120 As a Promising Frontline Therapy

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Preclinical and Clinical Evidence for Erythroid-Stimulating Activity of RVU120 CDK8/19 Inhibitor in AML and MDS

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Safety and Efficacy Results from CLI120-001 a Phase 1 Study in RR-AML and HR-MDS: Update from Higher Dose Levels

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy

Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial)

Clinical Characteristics of Isolated CNS Relapse after Allogeneic Transplantation for AML — Poor Outcomes Despite Longer Time to Relapse

FLT3 Positivity Is a Predictor of Early Relapse Post-Transplantation — Allo-HCT Is an Ineffective Salvage Strategy in Active AML

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

Pretransplant Clinical Factors Can be Used to Predict the Risk of Cytokine Release Syndrome after Haploidentical Peripheral Blood Transplantation

Outcomes of Patients with Baseline Marrow Fibrosis at Allogeneic Hematopoietic Cell Transplantation

Tocilizumab Is Safe after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only